November 14, 2023 07:06 AM EST

AstraZeneca's concurrent Imfinzi-chemo-radiation combo in lung cancer misses primary endpoint in PhIII trial

Katherine Lewin

News Reporter

AstraZeneca’s PD-L1 Imfinzi failed a Phase III trial in non-small cell lung cancer (NSCLC) when investigated concurrently with chemoradiotherapy (CRT) as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca's concurrent Imfinzi-chemo-radiation combo in lung cancer misses primary endpoint in PhIII trial

Katherine Lewin

News Reporter

Sign up to read this article for free.

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves subcutaneous version of Bristol Myers' Opdivo

WuXi AppTec will sell cell and gene therapy business to private equity firm

CagriSema’s weight loss data disappointed. What does Novo do next?

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

As­traZeneca's con­cur­rent Imfinzi-chemo-ra­di­a­tion com­bo in lung can­cer miss­es pri­ma­ry end­point in PhI­II tri­al

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

AstraZeneca's concurrent Imfinzi-chemo-radiation combo in lung cancer misses primary endpoint in PhIII trial

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves subcutaneous version of Bristol Myers' Opdivo

WuXi AppTec will sell cell and gene therapy business to private equity firm

CagriSema’s weight loss data disappointed. What does Novo do next?

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify